In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inside Bayer Oncology: An Interview With Robert LaCaze

Executive Summary

Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.

Advertisement

Related Content

Oncology Disruption Demands Strategic Transformation
Cancer Drugs Boost Bayer Despite Crop, Consumer and Currency Concerns
Bayer And Morphosys Brush Off ADC Mesothelioma Failure
Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize?
Stivarga Filings Reinforce Bayer’s HCC Position, For Now

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV005164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel